Multivariate analysis for overall survival (OS) in cytogenetically normal AML
| Variables . | HR . | 95% CI . | P* . |
|---|---|---|---|
| Overall survival | |||
| miRNA-106† | 1.69 | 1.09-2.62 | .018* |
| FLT3ITD‡ | 2.34 | 1.16-4.69 | .017* |
| NPM1§ | 0.21 | 0.09-0.48 | <.0001 |
| CEBPA‖ | 0.92 | 0.44-1.92 | .82 |
| WBC count¶ (×109/L) | 1.52 | 1.14-2.02 | .004* |
| Age# | 1.03 | 1.00-1.06 | .036* |
| Variables . | HR . | 95% CI . | P* . |
|---|---|---|---|
| Overall survival | |||
| miRNA-106† | 1.69 | 1.09-2.62 | .018* |
| FLT3ITD‡ | 2.34 | 1.16-4.69 | .017* |
| NPM1§ | 0.21 | 0.09-0.48 | <.0001 |
| CEBPA‖ | 0.92 | 0.44-1.92 | .82 |
| WBC count¶ (×109/L) | 1.52 | 1.14-2.02 | .004* |
| Age# | 1.03 | 1.00-1.06 | .036* |
Cox proportional hazard model for multivariable analyses of miRNA-106 as prognostic marker for overall survival. Analyses included 85 cytogenetically normal acute myeloid leukemia patients with age ≤ 60 years.
HR indicates hazard ratio; CI, confidence interval; FLT3ITD, FLT3 Internal Tandem Duplications; NPM1, Nucleophosmin; CEBPA, CCAAT-enhancer binding protein alpha; and WBC, white blood cell.
P ≤ .05.
miRNA-106 expression is used as a continuous variable.
FLT3ITD versus no FLT3ITD.
NPM1 mutation versus no NPM1 mutation.
CEBPA mutation versus no CEBPA mutation.
WBC count > 20 × 109/L versus < 20 × 109/L.
Age is used as a continuous variable.